Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Russia Stocks Close Flat as MOEX Hits 1-Month High 
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
Netflix’s $72 Billion Warner Bros Discovery Deal Reshapes the Entertainment Landscape 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Gold Prices Edge Higher as Markets Await Key U.S. PCE Inflation Data 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
U.S. Stocks End Week Higher as Markets Anticipate Fed Rate Cut 
U.S.-EU Tensions Rise After $140 Million Fine on Elon Musk’s X Platform 
Spirit Airlines Reverses Pilot Furlough Plans Amid Updated Staffing Outlook 
Mizuho has unveiled its January US Top Picks, spotlighting Chewy, GE Vernova, Enliven Therapeutics, Quest Diagnostics, DuPont, and Salesforce. These companies align with Mizuho’s high-conviction investment ideas, driven by expected catalysts over the next year.
Chewy earned a spot for its strong EBITDA margin expansion, supported by automation, vet-focused initiatives, and app engagement. With a $42 price target, analysts see a 17% upside for the pet retailer.
GE Vernova stands out as a key player in power generation, providing turbines and grid equipment that supply 30% of global electricity. Mizuho forecasts significant growth in natural gas power contracts by 2025, driven by rising data center demand.
Enliven Therapeutics shows promise with ELVN-001, an investigational tyrosine kinase inhibitor (TKI) demonstrating early efficacy in chronic myeloid leukemia (CML). Analysts see potential for ELVN-001 to expand into first-line treatment, bolstering its market outlook.
Quest Diagnostics appeals for its stable cash flow and growth opportunities in diagnostics, underpinned by Medicare and commercial pricing strength. Mizuho highlights its acquisition pipeline and EPS growth forecast for 2025.
DuPont’s planned split into ElectronicsCo, WaterCo, and the new DuPont is seen as a value catalyst. Analysts cite the company’s leadership in specialty materials like Kevlar and Tyvek, alongside seasonal sales recovery and electronics growth.
Salesforce rounds out the list, with Data Cloud and Agentforce technology driving productivity and revenue growth. Upcoming updates, multi-cloud deals, and margin improvements position Salesforce for continued success in digital transformation.
These additions reflect Mizuho’s strategic outlook for 2024, showcasing diverse opportunities across industries.
